Get notified when HUMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Existential event
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, and the auditor's report includes an explanatory paragraph.
Humacyte prices $50M primary offering at $1.05/share; net proceeds $46.8M to fund Symvess commercialization
Filed June 11, 2026 · ~1 min read
Key Changes
-
high
Humacyte is offering 47,619,048 shares at $1.05 per share, raising $50M gross; net proceeds to the company are $46.8M.
The Offering verify on EDGAR → -
high
Net proceeds will fund Symvess commercialization, a BLA supplement for hemodialysis, pipeline development, and working capital.
Use of Proceeds verify on EDGAR → -
high
Investors face immediate dilution of $0.81 per share (77% of the offer price) based on as-adjusted net tangible book value.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.
Partner
Trade HUMA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify